Halliburton SEC Filings

Halliburton Company executive Sarah I. Rubenfeld, SVP & Chief Accounting Officer, reported a new stock award in company shares. On 01/02/2026 she acquired 5,610 shares of Halliburton common stock under the Halliburton Company Stock and Incentive Plan, based on a New York Stock Exchange closing price of $29.60 on the grant date. The plan allows shares to be surrendered back to Halliburton to cover tax withholding obligations.

After this grant, she beneficially owns 73,310.422 Halliburton shares, which includes 15.422 shares purchased through the Employee Stock Purchase Plan for the period ending September 30, 2025. She also holds options to buy 9,688 shares at an exercise price of $49.61 exercisable from January 2, 2018 until January 2, 2028, and options to buy 7,994 shares at $55.68 exercisable from January 3, 2017 until January 3, 2027.

Halliburton Company executive insider activity: The President - Eastern Hemisphere of Halliburton reported equity transactions effective 01/02/2026. The executive received 41,156 shares of common stock under the Halliburton Company Stock and Incentive Plan, with the grant referenced to a closing share price of $29.60. The filing also shows the vesting of 3,552 restricted stock units from an award granted in January 2025, which converted into common shares.

After these transactions, the executive beneficially owned 70,991 shares of Halliburton common stock directly. The report lists remaining derivative holdings, including 14,204 restricted stock units and several stock option awards with exercise prices ranging from $24.68 to $49.61 and expirations between 2026 and 2030. Each restricted stock unit represents the right to receive one share of common stock as it vests in equal annual installments.

Halliburton Company disclosed an insider equity transaction by its Executive Vice President & Chief Financial Officer. On January 2, 2026, the officer acquired 37,548 shares of common stock as an award under the Halliburton Company Stock and Incentive Plan at the New York Stock Exchange closing price of $29.60 per share on the grant date. Following this award, the officer beneficially owned 159,719.623 shares, which includes 166.852 shares accumulated through dividend reinvestment as of December 31, 2025. The filing also notes that a stock option covering 9,534 shares with a $34.48 exercise price expired on January 4, 2026, while other stock options remain outstanding.

Halliburton Company reported that an executive serving as EVP, Secretary and Chief Legal Officer acquired additional common stock in the company. On January 2, 2026, the executive received 34,968 shares of Halliburton common stock as an award under the Halliburton Company Stock and Incentive Plan, which allows shares to be surrendered to cover tax withholding. The closing price of Halliburton common stock on the grant date was $29.60 per share.

Following this grant, the executive directly beneficially owns 368,496.49 shares of Halliburton common stock. In addition, the executive holds an option to buy 54,348 shares of common stock at an exercise price of $23.57 per share, which is exercisable and expires on January 15, 2030.

Halliburton Company’s Director, President & CEO reported a new stock award. On January 2, 2026, the executive acquired 133,458 shares of common stock at a value based on the New York Stock Exchange closing price of $29.60 per share. The shares were granted under the Halliburton Company Stock and Incentive Plan, which allows shares to be surrendered back to the company to cover tax withholding obligations.

Following this grant, the executive beneficially owns 1,131,090.02 shares of Halliburton common stock directly. The filing also lists existing stock options, including options to buy 171,200 shares at $31.44 expiring on December 5, 2028, 128,500 shares at $43.38 expiring on December 6, 2027, and 69,500 shares at $53.54 expiring on December 7, 2026.

A shareholder of HAL has filed a notice of intent to sell 100,000 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $3,225,000.00. The shares are expected to be sold on the NYSE around January 5, 2026, and the company had 841,626,610 shares outstanding at the time referenced.

The shares to be sold were accumulated over many years, primarily through restricted stock vesting as compensation from the issuer and purchases under an employee stock purchase plan funded with cash. The person selling the shares represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.

Halliburton Company director reports equity awards and deferred stock units. A Halliburton Co (HAL) director filed details of equity-based compensation, including stock equivalent units and restricted stock units that convert to common stock on a one-for-one basis.

On 12/30/2025, the director acquired 1,211.885 stock equivalent units under the Halliburton Company Directors' Deferred Compensation Plan, which are settled in common stock after service as a director ends. These units, along with prior accruals, totaled 12,940.639 derivative securities beneficially owned directly after the transaction.

The filing also lists several restricted stock unit awards, each representing the right to receive one share of common stock. Awards include 7,485 units from 12/2025, 7,485 units from 12/2024, 6,264.53 units from 12/2023, 5,070.76 units from 03/2023, and 4,052.66 units, all held directly. The restricted stock units generally vest in one year on the first anniversary of the award, with shares delivered either upon vesting or following cessation as a director if deferral was elected.

Halliburton Company insider holdings are reported for an officer serving as President - Eastern Hemisphere. The reporting person beneficially owns 26,283 shares of common stock in direct form.

The filing also lists several stock options to buy common stock, including options exercisable through dates ranging from 08/14/2026 to 01/02/2030, covering 11,775, 9,517, 4,323, and 7,829 underlying shares at exercise prices between $24.68 and $49.61 per share. In addition, the officer holds 17,756 restricted stock units granted in 01/2025, which vest in five equal annual installments, with one company share delivered for each unit as it vests.

Halliburton Company reported director equity activity involving restricted stock units and common shares on December 5, 2025. A block of 6,092 shares of common stock was acquired at a price of $0 following the exercise of derivative securities, increasing the director's directly held common stock to 21,375 shares.

In the derivative table, 7,485 restricted stock units granted in December 2025 were acquired, each representing one share of common stock, with 7,485 derivative securities beneficially owned afterward. Another 6,092 restricted stock units from a December 5, 2024 grant were converted, leaving no units remaining from that grant. The restricted stock units vest in one year on the first anniversary of the award, with shares delivered upon vesting or, if elected, after the director ceases service.